Farallon Capital Management LLC Purchases 458,000 Shares of Encompass Health Co. (NYSE:EHC)

Farallon Capital Management LLC increased its holdings in shares of Encompass Health Co. (NYSE:EHC) by 15,266.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 461,000 shares of the company’s stock after acquiring an additional 458,000 shares during the quarter. Farallon Capital Management LLC owned approximately 0.46% of Encompass Health worth $42,573,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tidal Investments LLC increased its holdings in Encompass Health by 5.7% during the third quarter. Tidal Investments LLC now owns 3,509 shares of the company’s stock worth $339,000 after buying an additional 188 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Encompass Health by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 1,947 shares of the company’s stock worth $180,000 after purchasing an additional 352 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Encompass Health by 5.2% in the 4th quarter. Nordea Investment Management AB now owns 94,514 shares of the company’s stock worth $8,797,000 after purchasing an additional 4,714 shares during the period. Miracle Mile Advisors LLC grew its holdings in Encompass Health by 3.0% during the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock valued at $354,000 after purchasing an additional 112 shares during the period. Finally, Pallas Capital Advisors LLC purchased a new stake in Encompass Health in the fourth quarter worth $237,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Down 1.1 %

EHC opened at $116.13 on Friday. The business’s fifty day simple moving average is $103.08 and its 200 day simple moving average is $99.78. Encompass Health Co. has a 52 week low of $82.74 and a 52 week high of $118.27. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a market cap of $11.70 billion, a PE ratio of 26.04, a P/E/G ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Encompass Health’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.12 earnings per share. As a group, research analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.59%. Encompass Health’s dividend payout ratio (DPR) is currently 14.05%.

Insider Transactions at Encompass Health

In other news, insider Elissa Joy Charbonneau sold 4,279 shares of the company’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the completion of the transaction, the insider now directly owns 11,958 shares of the company’s stock, valued at approximately $1,394,422.38. This represents a 26.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,321 shares of company stock worth $2,142,452. Company insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on EHC shares. Barclays increased their price target on Encompass Health from $118.00 to $129.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Royal Bank of Canada lifted their target price on shares of Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, April 28th. KeyCorp boosted their target price on shares of Encompass Health from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Truist Financial reiterated a “buy” rating and issued a $135.00 price target (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Finally, UBS Group lifted their target price on Encompass Health from $117.00 to $130.00 and gave the company a “buy” rating in a report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $120.86.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.